AVI 6002

Drug Profile

AVI 6002

Alternative Names: AVI-6002; AVI-7357/AVI-7539; AVI-7539/AVI-7357

Latest Information Update: 09 Oct 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AVI BioPharma; United States Army Medical Research Institute of Infectious Diseases
  • Developer Sarepta Therapeutics; United States Army Medical Research Institute of Infectious Diseases
  • Class Antisense elements; Antisense oligonucleotides; Antivirals
  • Mechanism of Action RNA interference; Viral RNA inhibitors; VP35 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Ebola virus infections

Most Recent Events

  • 02 Oct 2012 Discontinued - Phase-I for Ebola virus infections in USA (IV)
  • 02 Aug 2012 Suspended - Phase-I for Ebola virus infections in USA (IV)
  • 12 Jul 2012 AVI BioPharma is now called Sarepta Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top